HomeAI · summaries
Storia in 4 fonti
Indian Pharma Billionaires Pile Into Generic Weight-Loss Drugs, Sparking Regulatory Scrutiny
Last week’s expiry of the patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions by some of India’s biggest pharma companies.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindu.com
Generic semaglutide widens access, but doctors warn of misuse and quality risks
Generic semaglutide increases accessibility, but doctors caution against misuse and quality concerns
- ·
cnbc.com
India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to stay on top
Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.
